Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English

Gene Therapy for Blood Disorder May be Effective

Beta-thalassemia is a genetic disorder that impairs the body's ability to produce a key component of hemoglobin -- a critical protein in red blood cells that carries oxygen to organs and tissue.

IANS

Updated:April 19, 2018, 3:22 PM IST
facebookTwitterskypewhatsapp
Gene Therapy for Blood Disorder May be Effective
Picture for Representation. (Photo: AFP)
Loading...

Gene therapy for patients with a severe form of the blood disorder beta-thalassemia could be safe and effective as well as end the need for transfusions, results from the clinical trials show.

Beta-thalassemia is a genetic disorder that impairs the body's ability to produce a key component of hemoglobin -- a critical protein in red blood cells that carries oxygen to organs and tissue.

People with the most severe forms of beta-thalassemia require monthly blood transfusions, right from their toddler age, to replenish their red blood cell supplies along with iron chelation to remove extra iron from the body.

Frequent transfusions, however, can cause serious complications due to iron toxicity and viral infections.

The results, published in New England Journal of Medicine, showed that a one-time treatment with the gene therapy known as LentiGlobin BB305 vector reduced or eliminated the need for blood transfusions in 22 patients with severe beta-thalassemia.

"We saw remarkable outcomes using LentiGlobin gene therapy, with most patients no longer needing monthly transfusions," said lead author Alexis Thompson, from Ann & Robert H. Lurie Children's Hospital of Chicago.

"These study results exceeded our expectations with clinical benefit for nearly all patients and suggest that gene therapy may be an effective treatment for thalassemia in the future," Thompson added.

Of the 22 patients aged between 12 and 35 years, 15 patients achieved transfusion-free status, while others needed transfusions less often.

All the patient underwent chemotherapy, after which they were infused with their own stem cells that were treated in the lab with a modified virus to replace the gene that is defective in thalassemia. Patients typically reached peak production of hemoglobin in 9-12 months after infusion.

"While these gene therapy trials were the largest for thalassemia to date, we need to evaluate effectiveness in a much larger population," Thompson said, adding that they "are now enrolling patients as young as five-years-old on a Phase 3 trial".

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months. Use code FREEDOM.

Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp

Live TV

Loading...
Countdown To Elections Results
To Assembly Elections 2018 Results